Akoya Biosciences and NeraCare enter into a license agreement
Seeking Alpha News (Tue, 10-Dec 9:41 AM ET)
Globe Newswire (Tue, 10-Dec 8:15 AM ET)
Globe Newswire (Mon, 9-Dec 8:00 AM ET)
Akoya Biosciences Reports Third Quarter 2024 Financial Results
Globe Newswire (Thu, 14-Nov 4:00 PM ET)
Globe Newswire (Tue, 5-Nov 8:00 AM ET)
Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024
Globe Newswire (Mon, 28-Oct 8:30 AM ET)
Globe Newswire (Mon, 7-Oct 8:00 AM ET)
Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors
Globe Newswire (Thu, 3-Oct 4:00 PM ET)
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
Akoya Biosciences trades on the NASDAQ stock market under the symbol AKYA.
As of December 11, 2024, AKYA stock price climbed to $2.56 with 240,872 million shares trading.
AKYA has a beta of 2.78, meaning it tends to be more sensitive to market movements. AKYA has a correlation of 0.15 to the broad based SPY ETF.
AKYA has a market cap of $126.88 million. This is considered a Micro Cap stock.
Last quarter Akoya Biosciences reported $19 million in Revenue and -$.21 earnings per share. This fell short of revenue expectation by $-7 million and missed earnings estimates by -$.01.
In the last 3 years, AKYA traded as high as $16.57 and as low as $1.88.
The top ETF exchange traded funds that AKYA belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
AKYA has underperformed the market in the last year with a return of -42.0%, while the SPY ETF gained +33.6%. In the last 3 month period, AKYA fell short of the market, returning -3.0%, while SPY returned +11.1%. However, in the most recent 2 weeks AKYA has outperformed the stock market by returning +16.4%, while SPY returned +1.2%.
AKYA support price is $2.21 and resistance is $2.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKYA shares will trade within this expected range on the day.